Dendritic cell-based cancer immunotherapy targeting MUC-1
/in Hypernephroma, International Publications /von 2005-10-27 / Cancer Immunol. Immunother. 2006 Jan;55(1):63-7Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef
/in HIV/AIDS, International Publications /von 2005-10-25 / Blood 2006 Mar;107(5):1963-9HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
/in Cervical Cancer, Dendritic Cells, International Publications /von 2005-10-24 / Gynecol Oncol 2006 Mar;100(3):469-78Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions
/in HIV/AIDS, International Publications /von 2005-10-13 / J. Clin. Invest. 2005 Nov;115(11):3265-75Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells
/in International Publications, Malignant Lymphoma /von 2005-10-07 / Hum. Immunol. 2005 Sep;66(9):938-49Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
/in International Publications, Prostate Cancer /von 2005-10-03 / Br. J. Cancer 2005 Oct;93(7):749-56The immunotherapy of prostate and bladder cancer
/in International Publications, Urothelial Carcinoma /von 2005-10-01 / BJU Int. 2005 Oct;96(5):728-35Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin’s lymphoma
/in International Publications, Malignant Lymphoma /von 2005-10-01 / Curr Gene Ther 2005 Oct;5(5):511-21[In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine]
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2005-10-01 / Zhonghua Xue Ye Xue Za Zhi 2005 Oct;26(10):593-7
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution